---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Indication questions"
description: "Indication questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Testing and Eligibility. Questions: What is Opdivo approved for in metastatic non-small cell lung cancer? What is Opdivo Qvantig approved for in metastatic NSCLC? Can Opdivo Qvantig be given with Yervoy for lung cancer? Does Opdivo plus Yervoy require PD-L1 testing in metastatic NSCLC? 1 further question follow. 5 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Indication questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Indication questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications: Indication](https://www.evicenter.com/medical-information/opdivo/indication).

## Indication

<a id="opdivo-nsclc-indication"></a>

### What is Opdivo approved for in metastatic non-small cell lung cancer?

> “OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult 
> patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an 
> FDA-authorized test [see Dosage and Administration (2.1)], with no EGFR or ALK genomic 
> tumor aberrations.
> •	 OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, 
> is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, 
> with no EGFR or ALK genomic tumor aberrations.
> •	 OPDIVO is indicated for the treatment of adult patients with metastatic NSCLC with 
> progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic 
> tumor aberrations should have disease progression on FDA-approved therapy for these 
> aberrations prior to receiving OPDIVO.”

Source: [OPDIVO: OPDIVO, page 3, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=3)

<a id="opdivo-qvantig-indication"></a>

### What is Opdivo Qvantig approved for in metastatic NSCLC?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “SUBCUTANEOUS USE: OPDIVO Qvantig® (nivolumab and hyaluronidase-nvhy), as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO Qvantig.”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=SUBCUTANEOUS%20USE%3A%20OPDIVO%20Qvantig%C2%AE%20%28nivolumab,prior%20to%20receiving%20OPDIVO%20Qvantig.)

<a id="opdivo-qvantig-with-yervoy"></a>

### Can Opdivo Qvantig be given with Yervoy for lung cancer?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “Limitations of Use: OPDIVO Qvantig is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC.”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=Limitations%20of%20Use%3A%20OPDIVO%20Qvantig,the%20treatment%20of%20metastatic%20NSCLC.)

> “OPDIVO Qvantig may not be used in combination with ipilimumab.”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=OPDIVO%20Qvantig%20may%20not%20be%20used%20in%20combination%20with%20ipilimumab.)

This passage is in a collapsed section of the page; select: How does OPDIVO Qvantig work?

## Testing

<a id="opdivo-pd-l1-testing"></a>

### Does Opdivo plus Yervoy require PD-L1 testing in metastatic NSCLC?

Applies to: First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

> “Select patients with metastatic NSCLC for treatment with OPDIVO in combination with 
> ipilimumab based on PD-L1 expression [see Clinical Studies (14.5)].”

Source: [OPDIVO: OPDIVO, page 3, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=3)

> “Information on FDA-authorized tests for patient selection is available at:
> https://www.fda.gov/CompanionDiagnostics”

Source: [OPDIVO: OPDIVO, page 3, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=3)

Note: The quoted PD-L1 selection statement applies to first-line Opdivo with Yervoy.

## Eligibility

<a id="opdivo-egfr-alk"></a>

### Can Opdivo be used for lung cancer with EGFR or ALK mutations?

> “INTRAVENOUS USE: OPDIVO® (nivolumab) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.”

Source: [OPDIVO: OPDIVO Qvantig® Efficacy Data for 2L mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/second-line-mnsclc/efficacy#:~:text=INTRAVENOUS%20USE%3A%20OPDIVO%C2%AE%20%28nivolumab%29%20is,aberrations%20prior%20to%20receiving%20OPDIVO.)

> “INDICATION: OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=INDICATION%3A%20OPDIVO%C2%AE%20%28nivolumab%29%2C%20in%20combination,or%20ALK%20genomic%20tumor%20aberrations.)

> “INDICATION: OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo Efficacy Data for NSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-nsclc/efficacy#:~:text=INDICATION%3A%20OPDIVO%C2%AE%20%28nivolumab%29%2C%20in%20combination,or%20ALK%20genomic%20tumor%20aberrations.)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
